Results 141 to 150 of about 5,315 (239)

Can a Lifestyle‐Centred, Low‐Dose Model Improve Hypertension and Diabetes Care in Low‐ and Middle‐Income Countries? Real‐World Implementation Data From Zambia

open access: yesLifestyle Medicine, Volume 7, Issue 3, July 2026.
ABSTRACT Introduction Hypertension and Type 2 diabetes are major contributors to the growing burden of non‐communicable diseases in rural Zambia. Lifestyle interventions are central to prevention and management, yet implementation remains limited in resource‐constrained settings.
Keith Birrell   +2 more
wiley   +1 more source

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. [PDF]

open access: yesDiabetes Obes Metab
Engström A   +10 more
europepmc   +1 more source

Clinical Characteristics of Diabetic Cardiovascular Autonomic Neuropathy in Korean Individuals With Type 2 Diabetes

open access: yesJournal of Diabetes, Volume 18, Issue 7, July 2026.
In long‐standing type 2 diabetes, cardiovascular autonomic neuropathy (CAN) was highly prevalent (88.4%), characterized by reduced heart rate variability (HRV) and prolonged QTc intervals. Advanced age and higher systolic pressure predicted CAN, indicating the importance of routine autonomic assessment and early blood pressure management, even with ...
Seon Mee Kang   +9 more
wiley   +1 more source

Influences of Fasting on Elimination of Sulfonylurea Compounds from Plasma in Rabbits

open access: yesYAKUGAKU ZASSHI, 1983
S, Tsukiai   +6 more
openaire   +3 more sources

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor‐Associated Ketoacidosis Case Reports

open access: yesActa Anaesthesiologica Scandinavica, Volume 70, Issue 6, July 2026.
ABSTRACT Introduction The use of sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in the perioperative setting may lead to SGLT2i‐associated postoperative ketoacidosis (SAPKA) in patients with type 2 diabetes (T2D). Therefore, cessation of this drug is recommended before surgery.
L. I. P. Snel   +11 more
wiley   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

open access: yesDiabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy